Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma

Frontiers in Medicine

Medicine

Loredana Albonici¹  Chiara Focaccetti¹  Roberto Bei¹  Camilla Palumbo¹  Loredana Cifaldi²  Monica Benvenuto³  Daniela Nardozi⁴  Valentina Angiolini⁴  Laura Masuelli⁴  Arianna Bei⁵  Alessandra Rufini⁶ 

[1] Department of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, Rome, Italy;Department of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, Rome, Italy;Academic Department of Pediatrics (DPUO), Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy;Department of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, Rome, Italy;Saint Camillus International University of Health and Medical Sciences, Rome, Italy;Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy;Medical School, University of Rome “Tor Vergata”, Rome, Italy;Saint Camillus International University of Health and Medical Sciences, Rome, Italy;Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy;

关键词: head and neck squamous cell carcinoma;    EGFR;    ErbB receptors;    Cetuximab;    immune checkpoint inhibitors;   

DOI  :  10.3389/fmed.2023.1066021

 received in 2022-10-10, accepted in 2023-01-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type, has often an aggressive course and is poorly responsive to current therapeutic approaches, so that 5-year survival rates for patients diagnosed with advanced disease is lower than 50%. The Epidermal Growth Factor Receptor (EGFR) has emerged as an established oncogene in HNSCC. Indeed, although HNSCCs are a heterogeneous group of cancers which differ for histological, molecular and clinical features, EGFR is overexpressed or mutated in a percentage of cases up to about 90%. Moreover, aberrant expression of the other members of the ErbB receptor family, ErbB2, ErbB3 and ErbB4, has also been reported in variable proportions of HNSCCs. Therefore, an increased expression/activity of one or multiple ErbB receptors is found in the vast majority of patients with HNSCC. While aberrant ErbB signaling has long been known to play a critical role in tumor growth, angiogenesis, invasion, metastatization and resistance to therapy, more recent evidence has revealed its impact on other features of cancer cells’ biology, such as the ability to evade antitumor immunity. In this paper we will review recent findings on how ErbB receptors expression and activity, including that associated with non-canonical signaling mechanisms, impacts on prognosis and therapy of HNSCC.

【 授权许可】

Unknown   
Copyright © 2023 Palumbo, Benvenuto, Focaccetti, Albonici, Cifaldi, Rufini, Nardozi, Angiolini, Bei, Masuelli and Bei.